A Pragmatic Trial of Interleukin-17 Inhibition Versus Janus Kinase Inhibition After Tumor Necrosis Factor-alpha Inhibitor Failure in Axial Spondyloarthritis

NCT ID
NCT07770646
Registry status
Not yet recruiting
Study type
Interventional
Phase
Phase 4
Sponsor
The University of Texas Health Science Center, Houston
Conditions
Axial Spondyloarthritis (AxSpA)

Overview

ClinicalTrials.gov lists this study as Not yet recruiting.

Official title: A Pragmatic Randomized Pilot Trial of Interleukin-17 Inhibition Versus Janus Kinase Inhibition After Tumor Necrosis Factor-alpha Inhibitor Failure in Axial Spondyloarthritis

Enrollment: 40 participants (Estimated).

What is being studied

  • Intervention: secukinumab
  • Drug: Secukinumab (IL-17i )
  • Intervention: upadacitinib
  • Drug: Upadacitinib (JAKi)

Who may be eligible

Ages
18 Years to no maximum
Sex
All
Healthy volunteers accepted
No

ClinicalTrials.gov lists the following eligibility criteria.

Inclusion Criteria: * fulfill ASAS classification criteria for axSpA and/or modified New York classification criteria for AS * Active axSpA (ASDAS ≥ 2.1 and/or BASDAI ≥ 4) * Failure of or intolerance to ≥1 TNF * Participants of reproductive potential must agree to use any form of effective contraception during the study period, in accordance with standard clinical practice and FDA labeling for the assigned study medication * Ability to provide informed consent Exclusion Criteria: * Previously received an IL-17i or JAKi * Active infection requiring antimicrobials * Contraindications to either treatment arm: * Inflammatory bowel disease (IBD)- Crohn's disease or Ulcerative Colitis * Active cancer or cancer remission within the past 3 years (apart from non-melanoma skin cancer (NMSC) and cervical intraepithelial neoplasia (CIN) * History of stroke, heart attack, or blood clots (venous or arterial) * Cirrhosis * End-stage renal disease (GFR \<15) or dialysis * Human Immunodeficiency Virus (HIV) positive * Pregnant or lactating * Concomitant use of other biologic or targeted synthetic disease-modifying anti-rheumatic drug (tsDMARD) therapy

Study locations

1 study location is listed.

Site recruitment status is not specified in the registry data for these locations.

Countries: United States

  • Texas, United States: 1

Sample of listed locations

  • The University of Texas health Science Center at Houston — Houston, Texas, 77030, United States — Site recruitment status not specified in the registry data

Study details

Start date
November 1, 2026
Primary completion date
September 15, 2028
Completion date
September 15, 2029
First posted
August 18, 2026

Source and update information

Source
ClinicalTrials.gov
NCT ID
NCT07770646
Registry last updated
October 14, 2026
QualifiedStudies registry data refreshed
October 19, 2026
QualifiedStudies record fetched
October 19, 2026

View NCT07770646 on ClinicalTrials.gov

Trial information can change. Confirm current study details with the study team or the registry.

About joining clinical research

Find clinical trials you may match with

QualifiedStudies can help you search for research opportunities related to your health. Availability of this specific study through QualifiedStudies has not been established.

Find clinical trials you may match with | Clinical trial FAQ